John Cramer, MD

@Jdcramer

Assistant Professor at Wayne State University. Head & Neck Oncologic Surgeon. Health services, quality improvement & outcomes researcher. All opinions my own.

Detroit, MI

Joined June 2009

181Following

268Followers

John Cramer, MD Retweeted

LARVOL@Larvol · 8 h

On Head and Neck Cancer Day, we’re sharing a list of top trials in #HNC from 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights…

431

John Cramer, MD@Jdcramer · Jul 22

New AJCC9V staging for HPV+ OPC refines nodal classification by incorporating ENE. Modest improvement—but we still face a disconnect between pathologic and clinical staging systems. #HNSCC #HPV #AJCC thelancet.com/journals/lanon…

229

John Cramer, MD Retweeted

AmAcadOtolaryngology@AAOHNS · Jul 16

In our latest Voices of #Otolaryngology episode, Amanda Dilger, MD, and Neelima Tummala, MD, share game-changing sustainability strategies with Rahul Shah, that ENT practices can start implementing today to make a difference. hubs.ly/Q03xxS2p0 #SustainableENT #AAOHNS #ENT

455

John Cramer, MD Retweeted

NEJM@NEJM · Jul 5

Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) nej.md/45X0Nuc Editorial: Harnessing Immunotherapy in Curative-Intent Treatment of Head and Neck Cancer nej.md/4e6T0fr #Oncology

19.0K

John Cramer, MD Retweeted

R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)@rbryanbell · Jun 12

Boom!💥 ⁦@FDA⁩ approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades. fda.gov/drugs/resource…

2.0K

John Cramer, MD Retweeted

R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)@rbryanbell · Jun 3

Great to be @ASCO for yet another plenary session featuring HNSCC. NIVOPOSTOP is POSITIVE! Exciting advance & option for high risk resected HPV- pts. But given the EFS benefit & reduction in DM seen in KN689 for stage 3 pts in particular, these results/trials are not equivalent.

709

John Cramer, MD Retweeted

AHNS@AHNSinfo · May 31

This #WorldNoTobaccoDay, learn how quitting can lower your risk of cancer in the mouth, throat & voice box: buff.ly/V4774yy Your health. Your choice. Your voice. #AHNS #TobaccoFree #CancerAwareness #HeadAndNeckCancer

2.0K

John Cramer, MD Retweeted

Melvin LK CHUA | FRCR, PhD, FASCO@DrMLChua · May 31

Very powerful and insightful discussion by Prof Kevin Harrington @royalmarsden on KN-630 and C-POST The slides speak volumes and it isn’t just about the timing of anti-PD-1 😜 @KaramLab @CJTsaiMDPhD @seanmmcbride @PBlanchardMD #ASCO2025 #Skincancer #Cutaneouscancer

3.0K

John Cramer, MD Retweeted

Journal of Clinical Oncology@JCO_ASCO · May 31

‼️ #ASCO25 simultaneous publication by Zandberg et al:  A Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma (cSCC). Read the full article: brnw.ch/21wT48e

3.0K

John Cramer, MD@Jdcramer · May 31

Adjuvant cemiplimab improves DFS in high-risk cSCC (HR 0.32). Among the strongest DFS signals I've seen. Starting ICI after RT may be key—avoids immune suppression. OS flat, likely due to high crossover. 🔗 nejm.org/doi/full/10.10…

148

John Cramer, MD Retweeted

C. Jillian Tsai, MD, PhD@CJTsaiMDPhD · May 23

#ASCO25 KEYNOTE-630 📒Adjuvant pembro after surgery and PORT for up to 9 cycles in high-risk locally advanced cutaneous squamous cell carcinoma did not improve RFS/OS. @DavidSherMD @DrJohndeAlmeida @KaramLab @xrtGenomics @imrtlee @MarcusButler_PM @seanmmcbride

4.0K

John Cramer, MD Retweeted

C. Jillian Tsai, MD, PhD@CJTsaiMDPhD · May 23

On the contrary, adjuvant cemiplimab improved DFS in a similar population of cSCC after surgery and PORT. @DrNeilGross @MCWardMD @KaramLab @MarcusButler_PM @DrJohndeAlmeida @svporceddu

975

John Cramer, MD Retweeted

Vlad C. Sandulache@VSandulache2025 · May 8

Proposal: for new oncology drugs or regimens for which clinical trial data conflict or are limited the FDA should offer 3 year conditional approval which becomes permanent only once the primary outcome is confirmed by a cooperative group-run real world prospective registry.

212

John Cramer, MD Retweeted

Pierre Blanchard, MD@PBlanchardMD · May 4

SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25

135

11.0K